News Opinion Editor's Corner AHA 2025 What’s Going to Be Hot at AHA 2025? Michael O'Riordan November 05, 2025
News Conference News AHA 2024 ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS Michael O'Riordan November 21, 2024
News Conference News AHA 2024 Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360 Michael O'Riordan November 18, 2024
News Conference News AHA 2022 ‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE Michael O'Riordan November 06, 2022
News Conference News AHA 2022 Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT Michael O'Riordan November 05, 2022
News Conference News AHA 2021 ApoB Gains Ground as Best Lipid Predictor of MI Risk Michael O'Riordan November 22, 2021
News Conference News AHA 2021 An Oral PCSK9 Inhibitor? Early Data Show Safety, Big LDL Drops Shelley Wood November 15, 2021
News Conference News AHA 2020 Both Statins and Placebos Produce ‘Very Real’ Side Effects: SAMSON Michael O'Riordan November 15, 2020
News Conference News AHA 2020 Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol Michael O'Riordan November 12, 2020
News Conference News AHA 2018 Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study Michael O'Riordan November 15, 2018
News Conference News AHA 2018 AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City Shelley Wood November 05, 2018
News Conference News AHA 2016 Impaired Coronary Flow Reserve May Represent Hidden Biological Risk for Women L.A. McKeown November 17, 2016